1. Training Task discussion : All of you have to read this
carefully. I made comments in detail on every article in the
training file. If anyone have any ideas or comments just write it
right below my post. 2. Inclusion & Exclusion Criterias: This
is very important. I have summarized and made a complete criteria
list for our screening step. Please read carefully to have a good
decision when you perform the screening step.3. Final excel data
(made by Anh Hoang Nguyen): please USE this file in the screening
step.Hint: Many of you lacks of experience when perform the
screening step so I will give some small hints:1. When you screen
the abstract in Endnote, some of them do not contain abstract info
(most of them come from Goolge scholar). Please copy the title and
search in Google or Pubmed library to find the abstract. If you
can't find, please note it in the Excel file "0 (can't find
abstract)"2. Some articles do not contain abstract and you see data
like this: "94th Annual Meeting of the American Association for
Cancer ResearchJuly 11-14, 2003Washington, DC, USA"--> This is
the poster, you do not need to search for abstract in Google or
Pubmed. 3. We only need the frequency or number of targeted
mutations so please DO NOT count the oncogene EXPRESSION in our
data. For example: If you see the article mentioned about RET
ONCOGENE expression, please ignore it. We only need datas for RET
rearrangement (or translocation or fusion - synonym terms used in
some studies).***Inclusion: 1-all articles were published up to now
2-articles containing information about PREVALENCE (or FREQUENCY) ,
NUMBER of BRAF OR RET OR RAS mutation in PAPILLARY THYROID
CARCINOMA. 3-no restriction is made with respect to language , age,
mutation detecting methods, tissue origin (FFPE, FNAB, or Frozen
tissues) and study designs.Careful: - We only need the frequency or
number of MUTATIONS so do not count oncogene expression in this
study.- Some studies regarding mutations in complex tumors (for
example: tumors containing both papillary carcinoma and other
carcinoma components) should be included in this study. We will
decide when we read full-textAttention: Additional Inclusion
criteria: no restriction is made with respect to TISSUE ORIGIN (for
example: Formalin-Fixed Paraffin Embedded (FFPE) OR Fine needle
Aspiration (FNA) OR Frozen tissues...)***Exclusion:1- Studies
involved in mutations in other types of thyroid cancer OR studies
focused on one specific variant of PTC (For example: Follicular
variant PTC or Cribriform-morular PTC...) OR studies focused on a
specific clinicopathological parameter (For example: Studies of
BRAF mutation in Lymph node metastatic PTC or extrathyroidal
extension PTC....)Careful: Many studies detected mutations in
various kinds of thyroid histology subtype, from malignancy to
bengin tumor. If PTC cases were included in these studies, you have
to pick up these studies.2-studies made on animals3-Studies
involved in possible etiologies of thyroid tumorigenesis (For
example: studies about RET/PTC rearrangement in areas surrounding
Chernobyl following the nuclear accident)Careful: Some studies
compared the mutation prevalence of population in areas surrounding
Chernobyl with population in areas NOT related with Chernobyl
accident. These studies should be added to the screening list
because we can use the data from areas NOT related with the nuclear
accident.4- Familial papillary thyroid carcinoma5- data could not
be extracted 6- data considerd as overlapping 7- Case report,
conference, poster and reviews8- Additional Exclusion criteria:
BRAF or RAS or RET/PTC studied in a specific clinicopathological
parameter: for example: studies of BRAF mutation in Lymph node
metastatic PTC ....1. When you screen the abstract in Endnote, some
of them do not contain abstract info (most of them come from Goolge
scholar). Please copy the title and search in Google or Pubmed
library to find the abstract. If you can't find, please note it in
the Excel file "0 (can't find abstract)"2. Some articles do not
contain abstract and you see data like this: "94th Annual Meeting
of the American Association for Cancer ResearchJuly 11-14,
2003Washington, DC, USA"--> This is the poster, you do not need
to search for abstract in Google or Pubmed. 3. We only need the
frequency or number of targeted mutations so please DO NOT count
the oncogene EXPRESSION in our data. For example: If you see the
article mentioned about RET ONCOGENE expression, please ignore it.
We only need datas for RET rearrangement (or translocation or
fusion - synonym terms used in some studies).
